Evidence map›Paper›PMID 37810185›Full record

ArticleRespiratory medicine case reports2023

Comprehensive genomic profiling of a metastatic small cell lung carcinoma with a complete and long-term response to atezolizumab: A case report.

Kresimir Tomic, Dragana Karan Krizanac, Faruk Skenderi, Kristina Krpina, Andrea Carapina Bilic, Kristina Galic, Zoran Gatalica, Semir Vranic

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Kresimir TomicDepartment of Oncology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Dragana Karan KrizanacDepartment of Pathology, Cytology and Forensic Medicine, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Faruk SkenderiDepartment of Pathology, UniMed Clinic, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.
Kristina KrpinaClinic for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia.
Andrea Carapina BilicDepartment of Family Medicine, Health Care Center Mostar, Mostar, Bosnia and Herzegovina.
Kristina GalicDepartment for Lung Diseases, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Zoran GatalicaConsultant Pathologist, Scottsdale, AZ, USA.
Semir VranicCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
University Clinical Hospital Mostar · BAQatar University · QASarajevo School of Science and Technology · BAUniversity Hospital Centre Zagreb · HRUniversity of Mostar · BAVitalant · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is a highly aggressive malignancy with a poor outcome. We present the case of a 57-year-old male patient with extensive-stage (ES-SCLC) treated with chemotherapy and atezolizumab. A complete response was achieved with a long remission of ∼three years. Comprehensive genomic profiling (CGP) of the tumor revealed high tumor mutation burden (13 mutations/Mb) and mutations of

Indexed as

AtezolizumabGenomic profilingImmunotherapyLung cancerSmall cell lung cancer

Identifiers

PMID37810185
PMCPMC10558768
OpenAlexW4387045252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.